cmx-001 and favipiravir

cmx-001 has been researched along with favipiravir* in 4 studies

Reviews

2 review(s) available for cmx-001 and favipiravir

ArticleYear
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10

    Ebola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results from in vitro models. We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based drugs, which are under development and being tested in animal models or in vitro using various cell types. Our paper discusses strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We underline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.

    Topics: Amides; Amidines; Androstenes; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral Agents; Benzofurans; Cytosine; Disease Models, Animal; Disease Outbreaks; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Immune Sera; Organophosphonates; Pyrazines; RNA, Small Interfering; Stilbenes; Virus Replication

2015
Current status of chemically synthesized inhibitors of Ebola virus.
    Recent patents on anti-infective drug discovery, 2014, Volume: 9, Issue:2

    The current Ebola virus outbreak is unprecedented in its scope and international impact. Given that there are currently no approved antivirals to treat Ebola virus, there is urgency to conduct more rapid development and evaluation of Ebola antivirals. Recently, the World Health Organization identified a number of antivirals as high priority to include AVI-6002 (AVI-7537 and AVI-7539), BCX4430, brincidofovir, favipiravir, and TKM-100802. This review describes these chemically synthesized inhibitors of Ebola virus, relevant patent development and gives an update on their current status.

    Topics: Adenine; Adenosine; Amides; Antiviral Agents; Cytosine; Drug Discovery; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Organophosphonates; Patents as Topic; Purine Nucleosides; Pyrazines; Pyrrolidines

2014

Other Studies

2 other study(ies) available for cmx-001 and favipiravir

ArticleYear
Infectious diseases. Ebola drug trials lurch ahead.
    Science (New York, N.Y.), 2015, Feb-13, Volume: 347, Issue:6223

    Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Clinical Trials as Topic; Cytosine; Disease Outbreaks; Ebolavirus; Hemorrhagic Fever, Ebola; Humans; Organophosphonates; Pyrazines

2015
[Ebola: three experimental clinical trials directed by MSF].
    Revue medicale suisse, 2014, Nov-26, Volume: 10, Issue:452

    Topics: Africa, Western; Amides; Anti-Infective Agents; Clinical Trials as Topic; Cytosine; France; Health Services Accessibility; Hemorrhagic Fever, Ebola; Humans; International Cooperation; Organophosphonates; Pyrazines; Societies, Medical

2014